QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.46

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.78 (+1.52%)

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.66 (-0.11%)

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.96 (+1.71%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.28 (+1.80%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

+3.95 (+1.65%)

USD 52.42B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.01 (+0.01%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 38.52B
0ZC:F Zscaler Inc

-2.66 (-1.48%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.11% 55% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.11% 51% F 51% F
Trailing 12 Months  
Capital Gain 8.92% 55% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.92% 51% F 51% F
Trailing 5 Years  
Capital Gain 55.96% 80% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.96% 80% B- 58% F
Average Annual (5 Year Horizon)  
Capital Gain 12.60% 79% B- 71% C-
Dividend Return 12.60% 76% C+ 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.02% 63% D 88% B+
Risk Adjusted Return 114.34% 98% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike